Skip to main content
< Back to news
Joan Feixas, Enantia's CEO (Photo: Daniel Portales, Barcelona Science Park).

Enantia develops an innovative Cannabinoids Cocrystal Platform

Enantia, a company with headquarters in the Barcelona Science Park and specialised in R&D process chemistry, solid form development and medicinal chemistry, has again succeeded in applying cocrystallisation technology to a new family of compounds: the cannabinoids.


Cannabinoids, especially cannabidiol (CBD) and tetrahydrocannabinol (THC), are known by their ability to interact with the endocannabinoid system, which play an important role in a number of biochemical pathways. Besides the only two approved drugs containing CBD, the potential of cannabinoids to be used to treat a large number of medical conditions is very high as is shown by the number of ongoing clinical trials. In addition, the changes in the laws that regulate the use of cannabis in different countries are fostering the use of cannabinoids in areas like medical cannabis, food and cosmetics, to mention a few.

Enantia has been working to apply cocrystallisation technology to cannabinoids with two objectives: to develop a highly efficient purification process from either natural or synthetic sources, and to obtain improved solid forms of different cannabinoids, notably CBD and THC, to be used as pharmaceutical actives.

“This research led us to the discovery of new cocrystals of CBD and the corresponding processes to prepare them. These cocrystals allow the purification of CBD (either from crude cannabis extracts or synthetic mixtures) with a simple, cost-effective and industrial scalable process. Furthermore, these new cocrystals can also be used as pharmaceutical ingredients in drug formulations. Enantia is open to discuss with possible partners the licensing of this technology for different uses”, says Joan Feixas, Enantia’s CEO.